Salt-tolerant endonucleases and the benefits for viral vector manufacturing, and a comparison of two marketed enzymes

Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format. 

Recombinantly produced Serratia marcescens endonucleases, such as DENARASE® and Benzonase®, are commonly applied for DNA removal in viral vector manufacturing processes. To further improve the solubility and thus manufacturing efficacy of viral vectors, higher salt concentrations can be applied. However, the activity of the commonly applied Serratia marcescens endonucleases is inhibited at higher salt concentrations. For this reason, producers of viral vectors increasingly look at alternative, more salt-tolerant endonucleases for nucleic acid digestion.

In this webinar, we want to introduce DENARASE® High Salt, an engineered variant of the Serratia marcescens wild-type enzyme. We will describe how the enzyme was optimized to become more tolerant to higher salt concentrations and explain how these conditions can streamline the viral vector manufacturing process. In addition, we will show data generated by a cell and gene therapy CDMO that compared DENARASE® High Salt with another commercially available salt-tolerant endonuclease (SAN HQ) in an AAV2 harvest.

Attend this webinar to:

• The benefits of higher salt concentrations in viral vector manufacturing
• The art and power of enzyme engineering
• How salt-tolerant endonucleases enable leaner viral vector processing
• A performance comparison of commercially available salt-tolerant endonucleases

Marc Struhalla

CEO at c-LEcta GmbH

Marc is the co-founder, shareholder, and managing director of c-LEcta. He earned a Ph.D. at the University of Hamburg following undergraduate studies in biochemistry at the University of Leipzig. After completing his Ph.D., he returned to the University of Leipzig before founding c-LEcta. Marc has more than 15 years of experience in product development and commercialization in the industrial biotech field and managed the closure of numerous strategic alliances with industry partners.

Svenja Michalek

Product Manager Biopharma at c-LEcta GmbH

Svenja is a product manager at c-LEcta. She is responsible for the biopharma portfolio, including the recently launched DENARASE High Salt. Svenja is dedicated to helping manufacturers alleviate pain points in their viral vector production process to facilitate the development and commercialization of cell and gene therapies. Prior to this, Svenja was working as a post-doctoral scientist in leukaemia research at the University of Konstanz. There she also earned her PhD following an MSc and BSc in Biological Sciences.

in 28

Days

Register

SPEAKERS

Marc Struhalla

CEO at c-LEcta GmbH

Svenja Michalek

Product Manager Biopharma at c-LEcta GmbH

You might also like

Unlocking mRNA-LNP potential using a novel lipid library combined with innovative analytical methods

Nejc Pavlin, Guillaume Freund

11 September

in 43

Days

Register

Development of an automated AAV capsid titer assay on a high-throughput platform

Matthew J.Lotti, John Chappell

3 September

in 35

Days

Register

Quickly and accurately measure key analytical attributes of viral vectors with macro mass photometry

Laura Pala

29 August

in 30

Days

Register

Extracellular vesicles: setting-up the path to IND with advanced characterization packages

Davide Zocco

28 August

in 29

Days

Register

Optimizing bioprocess purification: effective nucleic acid removal in high salt environments

Joanna Niska-Blakie, Eleonora Turco

22 August

in 23

Days

Register